A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

Aderans

Status and phase

Completed

Phase 2

Conditions

Female Pattern Baldness

Male Pattern Baldness

Androgenetic Alopecia

Treatments

Biological: Autologous cultured dermal and epidermal cells

Study type

Interventional

Funder types

Industry

Identifiers

NCT01451138

CA-0004541

Details and patient eligibility

About

The purpose of this study is to evaluate the ability of injections of Ji Gami(TM) N and Ji Gami(TM) NDO to induce hair growth in male and female subjects with hair loss.

Enrollment

40 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male and female volunteers 18 to 65 years old, inclusive
Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle.
Able to provide informed consent after risks and benefits of the study have been explained.
Be willing to undergo all study procedures.
Ability to communicate effectively with study personnel.
Have no clinically significant disease or abnormal laboratory evaluations taken at the screening visit.
Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study.

Exclusion criteria

Known sensitivity to DMEM/F-12 or any component of the study material.
Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
A history of drug or alcohol abuse within 1 year of study enrollment.
Participation in any other investigational study within 30 days or six half lives of its biologic activity, whichever is longer, before the scalp excision visit(s), and during the time enrolled in this study.
Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
Clinically significant abnormal laboratory parameters.
A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
Clinically significant dermatologic condition in donation or study areas.
Prior surgery in the donor or study areas.
Insufficient hair or scarring in the donor area that might impact cell growth.
Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.